How to access Zynteglo in Qatar: the named-patient access pathway, 2026
By the Reserve Meds Clinical and Regulatory Team. Last reviewed 2026-05-31.
Zynteglo (betibeglogene autotemcel) is FDA-approved for transfusion-dependent beta-thalassemia in patients who require regular red blood cell transfusions. It is not locally registered with Qatar's MOPH. Patients whose haematologists have recommended it can pursue access through MOPH's named-patient import framework. Reserve Meds coordinates the sourcing, documentation, and cold-chain logistics for Qatar-based patients.
Request access to Zynteglo in Qatar
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
The clinical situation
Zynteglo (betibeglogene autotemcel) is an autologous ex vivo lentiviral gene therapy developed by Bluebird Bio. The FDA approved it in August 2022 for transfusion-dependent beta-thalassemia (TDT) in adult and pediatric patients who require regular red blood cell transfusions. A lentiviral vector inserts a functional beta-A-T87Q-globin transgene into the patient's own CD34+ haematopoietic stem and progenitor cells. After myeloablative conditioning and reinfusion, the edited cells restore haemoglobin synthesis. In the pivotal Northstar and HGB trials, the majority of treated patients achieved transfusion independence or a substantial reduction in transfusion burden.
Beta-thalassemia carrier rates in the Gulf Arab population are elevated, and Qatar's TDT population has historically relied on chronic transfusion programmes and iron-chelation therapy. Zynteglo offers a one-time intervention that, for eligible patients, addresses the underlying haemoglobin deficit rather than managing it continuously.
Is Zynteglo available in Qatar?
Zynteglo is not currently registered with Qatar's Ministry of Public Health (MOPH), specifically through the Pharmacy and Drug Control Department (MOPH-PD). When a drug is not MOPH-registered, the mechanism for a Qatari-licensed physician to obtain it for a specific patient is MOPH-PD's named-patient import authorisation. This mechanism allows a treating physician at a registered facility to apply for the import of an unregistered medicine for a specific named patient where the drug is approved by a recognised reference authority (the US FDA qualifies) and no clinically suitable locally registered alternative exists.
Reserve Meds builds the documentation packet that supports the treating physician's application. We manage US-side sourcing and cold-chain logistics. The application is filed by the dispensing hospital's pharmacy team and the treating consultant. We do not contact MOPH-PD directly on behalf of families.
How the pathway works
A Qatari-licensed haematologist at a registered facility (typically within the Hamad Medical Corporation network or a licensed private hospital) initiates the MOPH-PD named-patient application. The application documents the patient's TDT diagnosis and severity, the prior transfusion history, the physician's clinical rationale for Zynteglo, and confirmation that no clinically equivalent locally registered alternative exists. Full product details, dispensing facility information, and a chain-of-custody plan accompany the clinical justification. Reserve Meds provides a documentation coordination kit to support the physician's filing. MOPH-PD routine review of a complete application typically runs 7 to 21 business days. Gene therapy cases with additional manufacturing complexity may run slightly longer. The four-to-six-month Bluebird Bio manufacturing period after cell collection means the regulatory review is not the binding constraint in most cases.
What your physician needs to know
Your treating haematologist initiates the named-patient application. Reserve Meds provides a coordination kit that covers the documentation structure, dispensing facility requirements, and chain-of-custody standards that MOPH-PD expects for gene therapy imports. The kit goes to your physician at intake. We do not publish the document checklist here; that is a concierge deliverable, not a self-service guide.
Tertiary facilities that handle named-patient imports as established workflow within Qatar include Hamad General Hospital in Doha, the National Center for Cancer Care and Research (NCCCR) at Hamad Medical Corporation, and Sidra Medicine in Doha for paediatric and rare-disease cases. Each maintains the pharmacy infrastructure appropriate to the storage requirements of the imported product.
Indicative cost and timing
Zynteglo's list price in the US is approximately USD 2.8 million for the one-time infusion product. The QAR is pegged to the US dollar at approximately 3.64 QAR to 1 USD, so the indicative drug cost is approximately QAR 10.2 million. Total cost of care, including workup, mobilisation, apheresis, the manufacturing wait, conditioning, inpatient admission, and first-year monitoring, is substantially higher. These are illustrative figures. Reserve Meds issues a full transparent quote at intake with every cost line itemised separately.
MOPH-PD routine review of a complete application typically runs 7 to 21 business days. The full treatment arc from first engagement to completed infusion is approximately one year, driven primarily by the manufacturing period. Families should plan around that timeline from first consultation.
Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not currently stocked; many require pre-authorisation. Reserve Meds provides the documentation set that supports the insurer's assessment. We do not guarantee coverage from any insurer.
Cost and timing figures are indicative. They reflect current market data and are not a guarantee. Reserve Meds provides a detailed quote at intake.
Reserve Meds's role
- Sourcing. US-side procurement through a DSCSA-compliant specialty channel with full serial traceability from Bluebird Bio through to the Qatari receiving pharmacy.
- Documentation. Coordination kit for the treating physician's MOPH-PD application; chain-of-custody attestation for the import file.
- Logistics. Validated cold-chain shipment with continuous temperature logging. The cold chain is managed from the US manufacturer through to the dispensing pharmacy's validated storage.
- Named case manager. A single coordinator assigned from intake through post-infusion follow-up, keeping the clinical team, the family, and the logistics track aligned.
Reserve Meds is not your treating physician. We do not practise medicine. We do not manufacture Zynteglo. We do not own or operate Hamad General Hospital, NCCCR, Sidra Medicine, or any other treatment centre. Clinical decisions remain with your treating haematologist. See reservemeds.com/trust for our full operating scope and limitations.
Frequently asked questions
Is Zynteglo available in Qatar?
Zynteglo (betibeglogene autotemcel) is FDA-approved for transfusion-dependent beta-thalassemia. It is not locally registered with Qatar's MOPH. Patients can access it through MOPH's named-patient import framework with a licensed haematologist's recommendation. Reserve Meds coordinates the documentation and logistics.
Is importing Zynteglo to Qatar legal?
Yes, when coordinated through MOPH's named-patient import mechanism with a QCHP-licensed physician's authorisation and compliant chain-of-custody documentation. Reserve Meds operates within this legal framework. See reservemeds.com/trust.
Which hospitals in Qatar can receive Zynteglo?
Hamad General Hospital, NCCCR (for adult oncology and haematology cases), and Sidra Medicine (for paediatric and rare-disease cases) are the primary tertiary facilities with named-patient import infrastructure. Your treating haematologist identifies the appropriate receiving facility.
Will Qatari insurance cover Zynteglo?
Hamad Medical Corporation public coverage, QLM, and GIG Gulf Qatar each assess named-patient imports case by case. Reserve Meds provides the documentation set that supports the insurer's prior-authorisation review. We do not guarantee coverage from any insurer.
How long does the pathway take?
MOPH-PD routine review typically runs 7 to 21 business days for a complete application. The manufacturing period after cell collection adds four to six months. Total arc from first engagement to infusion is approximately one year.
Next step: request access
If your Qatari physician has recommended Zynteglo and you are weighing the named-patient pathway, the next step is a short intake. We confirm eligibility and pathway fit within 24 to 48 hours and send a documentation kit to your haematologist.
Reserved for you.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating haematologist.
Clinical and regulatory review: Reserve Meds Clinical and Regulatory Team. Last medically reviewed: 2026-05-31.